Viscoelastic point-of-care testing to guide transfusion and antithrombotic therapy in perioperative and critically ill patients: are all parameters created equal?
Viscoelastic point-of-care (VE-POC) testing platforms, including ROTEM® (Tem Innovations GmbH, Basel, Switzerland), TEG® (Haemonetics, Braintree, MA, USA) and Sonoclot® (Sienco Inc., Boulder, CO, USA), although now typically managed by haematology laboratories, have been increasingly used to guide the management of patients who are either actively, or at high risk of, bleeding 1 . VE-POC tests have the theoretical advantages of assessing the whole coagulation process (hence, also called global haemostatic assays) and can be used near the patient in the operating theatre and ICU. Although different VE-POC tests all use whole blood, there are important differences in how the in vitro coagulation process is activated, and this is manifest in how different parameters exist between various platforms, how they are determined, and which part of haemostasis they are intended to assess. Furthermore, different terminologies are used to describe similar parts of the coagulation process, which can be confusing to many clinicians.
Broadly speaking, there are three possible purposes in using VE-POC tests in the perioperative and critical care setting. Firstly, they may be used to guide transfusion management in patients with critical bleeding 2,3 . Secondly, they may be used to identify patients who are hypercoagulable and at risk of thrombotic complications [4] [5] [6] . Thirdly, they may be used to assess the effects of systemic anticoagulants, with an aim to optimise dosing 7, 8 . Although these three purposes of VE-POC are intrinsically inter-related, there are also important fundamental reasons why they should be kept distinct. Within this context, we can understand why VE-POC can still be useful, despite the discordance between the ROTEM clotting time (CT) and activated partial thromboplastin time (aPTT), as reported by Prakash et al in this issue of Anaesthesia and Intensive Care.
Which VE-POC parameter is most useful in guiding transfusion therapy in critical bleeding?
In a systematic review of 11 randomised controlled trials (RCTs) of 1089 cardiac surgical patients 2 , use of VE-POC was associated with a reduction in red blood cell, fresh frozen plasma, and platelet transfusion compared to the control. However, this was not translated into more important clinical endpoints, including length of hospital stay, re-bleeding, and mortality. Furthermore, there was also no reduction in fibrinogen concentrate or cryoprecipitate transfusion, nor consistent reduction in bleeding, across most of the studies. There are two possible explanations for these results. First, abnormal standard coagulation test results, such as a prolonged International Normalized Ratio or aPTT may not need to be corrected, even in patients at risk of bleeding. Clinicians may be more confident in not giving blood products if they are assured by a normal VE-POC tracing. Second, emerging evidence suggests that fibrinogen plays a vital role in critical bleeding 10 . Because platelets and fibrinogen are the major determinants of the 'thickness' of the VE-POC tracing (e.g. maximum amplitude in TEG or maximum clot firmness or amplitude at ten minutes [A10] in ROTEM or FIBTEM® [Tem Innovations GmbH]) 11 , hypofibrinogenaemia can be easily diagnosed and corrected with fibrinogen or cryoprecipitate if a patient is managed according to the VE-POC results. This may explain why fibrinogen usage was not reduced when VE-POC was used to guide transfusion compared to the controls in the RCTs. Recent RCTs also showed that the use of fibrinogen transfusion as a first-line therapy to maintain a 'thick' VE-POC tracing (e.g. amplitude at ten minutes >13 mm versus 8 mm) was associated with a reduction in blood loss and red blood cell transfusion in craniosynostosis and cardiac surgery 3, 12, 13 .
CT on ROTEM or reaction time ('r-time') on TEG indicates the time for the first strands of fibrin to form, and is predominantly determined by the activity of the coagulation factors. Although many VE-POC algorithms will suggest fresh frozen plasma be administered for patients with a prolonged CT or r-time, outcome data after using this parameter alone to guide transfusion therapy in RCTs is lacking. Overall, it appears that the 'thickness' of the VE-POC tracing is more useful than the CT or r-time in guiding transfusion therapy in critical bleeding.
Which VE-POC parameter is most useful in predicting thrombotic complications?
Thrombosis and haemostasis are two sides of the same coin in coagulation. A 'thick' VE-POC has been shown to be associated with an increase in plasma procoagulant microparticles and risk of clinical thromboembolic events in patients with cancer 14 . The prothrombotic significance of a 'thick' VE-POC was also confirmed by different studies in patients during the perioperative period 5, 6 . A short CT or r-time has also been reported to be associated with a prothrombotic state 14 . This parameter is, however, lower in female patients 15 , as well as in the presence of systemic inflammation or sepsis 16 . Conversely, the CT or r-time can be lengthened in the presence of endogenous heparinoids in sepsis or acute liver failure 17, 18 . Because a number of factors can change the CT or r-time, a short CT or r-time is less reliable than a thick VE-POC tracing in detecting hypercoagulability, and as a predictor of thrombotic complications.
Can CT or r-time be used to guide antithrombotic therapy?
Unfractionated heparin (UFH), low molecular weight heparin and heparinoids all have a dose-related, but highly variable, effect on the relationship between CT or r-time and anti-Xa concentrations (Figure 1) 7 . More importantly, the relationships between CT or r-time and aPTT also vary substantially at different anti-Xa concentrations. With UFH, the r-time appears to reach a plateau at about 60 minutes, while aPTT continues to increase when anti-Xa concentrations are >0.2 IU/ml; but for low molecular weight heparin and danaparoid, the r-time also increases with increasing anti-Xa concentrations and, as expected, with minimal increases in aPTT.
Theoretically, the difference between the CT in the HEPTEM® (Tem Innovations GmbH) and INTEM® (Tem Innovations GmbH) (or r-time in the heparinase and non-heparinase TEG) can be used to detect the presence of heparin and estimate the magnitude of its effect 19 . In cardiac surgical patients, the doses of protamine sulphate needed to normal-ise the r-time on TEG and activated clotting time are indeed similar 8 . However, in patients treated with extracorporeal membrane oxygenation (ECMO), similar evidence is lacking. As severe systemic inflammation is expected in patients treated with ECMO, it is possible that the baseline CT in INTEM (or r-time in TEG) without heparinase will be well below normal when no heparin is used. How the baseline CT without heparin will correspond to the aPTT in patients on ECMO remains unknown. Consequently, without using the HEPTEM panel to define the baseline CT, it is not surprising for the study by Prakash et al to conclude that the absolute value of the CT in the INTEM did not correlate closely with aPTT 9 . To make the matter more complicated, acquired von Willebrand syndrome, which can increase aPTT but not the CT or r-time, is very common (>95%) in patients treated with ECMO 20,21 .
Given these concerns, are there any roles for using CT or r-time to guide antithrombotic therapy? First, if the CT or r-time is corrected with heparinase, we can confirm that a systemic anticoagulation effect of UFH or low molecular weight heparin is present. Second, it would be premature to use this parameter alone without aPTT or activated clotting time to titrate the doses of UFH, especially if a heparinase panel is not used as a control. Third, a recent small RCT failed to confirm that titrating enoxaparin doses with the r-time (in the heparinase TEG) could reduce the incidence of venous thromboembolism in trauma and surgical patients 22 . As such, whether the CT or r-time on the VE-POC tracing is useful in guiding thromboprophylaxis remains scientifically unproven. Finally, a newer version of ROTEM (LowTF-ROTEM®), using minimal amounts of tissue factor as an activator, is now available. The CT in the LowTF-ROTEM appears to correlate linearly with the increasing plasma concentrations of oral anti-Xa agents (e.g. apixaban and rivaroxaban) 23 , offering a possible quick and reliable alternative to plasma anti-Xa activity in titrating the doses of oral anti-Xa agents.
In summary, despite the limitations of VE-POC testing 1 , it does give us additional information about a patient's coagulation system above the standard haematology blood tests. The 'thickness' of the VE-POC tracing (maximum amplitude on TEG or maximum clot firmness/amplitude at ten minutes on INTEM or FIBTEM) appears to be most useful in guiding transfusion and predicting thrombotic complications. The CT or r-time on the VE-POC tracing can be affected by the activity of the coagulation factors, underlying pathological conditions of the patient, and different types of anticoagulants in a variable fashion. All things considered, perhaps aPTT and activated clotting time should remain as the gold standard in adjusting the doses of UFH for patients on ECMO. Health, and his work on venous thromboembolism is, in part, funded by an ANZCA project grant (15/010).
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